Treventis Corporation

Treventis Corporation is a Canadian biopharmaceutical company headquartered in Toronto, Ontario, dedicated to treating and preventing protein misfolding diseases. Its core asset is a proprietary, patented discovery engine called Common Conformational Morphology (CCM), which is used to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development across in vitro, ex vivo and in vivo settings, enabling rational drug design against misfolded proteins. The company's lead program, developed in partnership with Takeda, focuses on anti-misfolding small molecules for Alzheimer's disease. Treventis also pursues CCM-driven efforts in oncology and other neurodegenerative diseases, some of which are funded by the U.S. Department of Defense (DOD). The company states that its CCM platform has active druggable models for Tau, alpha-synuclein, p53 and amylin, with the potential to build models for more than 160 additional targets. Treventis organizes its pipeline around oligomer inhibitors, including a Tau oligomer inhibitor, an Aβ oligomer inhibitor and a broad-spectrum TDP oligomer inhibitor. Its stated therapeutic areas include Alzheimer's disease and tauopathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease and cancer. The company is led by Chief Executive Officer Christopher J. Barden, with Donald F. Weaver as Chief Medical Officer, Mark Reed as Chief Technology Officer and Marcia Taylor as Chief Scientific Officer. Its board includes Chairman and Founder L. William McIntosh and Founder William Wong, alongside independent directors Gregory Harriman and Timothy J. Williamson. An advisory board of scientific experts supports the company. As a private, venture-stage drug discovery company, Treventis does not disclose public financial statements. Its visibility rests on its CCM technology platform, its Takeda-partnered Alzheimer's program and its government-funded research in oncology and neurodegeneration.

Treventis Corporation is a Canadian biopharmaceutical company based in Toronto, Ontario, focused on treating and preventing protein misfolding diseases. The company was founded by L. William McIntosh, who serves as Chairman, and William Wong, both of whom remain associated with the company's board. Its scientific foundation rests on a proprietary, patented discovery engine known as Common Conformational Morphology (CCM), which the company uses to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development across in vitro, ex vivo and in vivo systems, enabling rational drug design against misfolded proteins. The company reports active druggable CCM models for Tau, alpha-synuclein, p53 and amylin, and states that the platform has the potential to generate models for more than 160 additional targets. Treventis's lead program, developed in partnership with Takeda, focuses on anti-misfolding small molecules in Alzheimer's disease. The company has also pursued CCM-driven efforts in oncology and other neurodegenerative diseases, with funding from the U.S. Department of Defense (DOD). Its pipeline is organized around oligomer inhibitors, including a Tau oligomer inhibitor, an Aβ oligomer inhibitor and a broad-spectrum TDP oligomer inhibitor. Stated therapeutic areas include Alzheimer's disease and tauopathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease and cancer. The company is led by Chief Executive Officer Christopher J. Barden, Chief Medical Officer Donald F. Weaver, Chief Technology Officer Mark Reed and Chief Scientific Officer Marcia Taylor, supported by biology and chemistry group leaders Seung-Pil Yang and Carlos Zepeda. Its board of directors includes Chairman and Founder L. William McIntosh, Founder William Wong and independent directors Gregory Harriman and Timothy J. Williamson. An advisory board of scientific experts, including Barry Greenberg, Gregory Kopia, Brian W. Metcalf and Patrick T. Shannon, provides additional guidance. As a private drug discovery company, Treventis does not publicly report financial results. Its profile in the life sciences sector derives from its CCM technology platform, its partnership with Takeda on an Alzheimer's program and its government-funded research in oncology and neurodegeneration.

• Treventis Corporation founded in Toronto, Canada, by L. William McIntosh and William Wong.

• Development of the proprietary, patented Common Conformational Morphology (CCM) discovery engine.

• Lead anti-misfolding small molecule program in Alzheimer's disease established in partnership with Takeda.

• CCM-driven research in oncology and other neurodegenerative diseases funded by the U.S. Department of Defense (DOD).

A technology-platform-driven, preclinical-stage drug discovery company focused on misfolded protein targets, partnering with large pharma and government funders.

• Common Conformational Morphology (CCM) discovery engine

  A proprietary, patented platform that identifies druggable active sites in misfolded protein targets using in silico models combined with in vitro, ex vivo and in vivo model development expertise.

• Tau oligomer inhibitor

  A pipeline program targeting Tau oligomers, relevant to Alzheimer's disease and tauopathy.

• Aβ oligomer inhibitor

  A pipeline program targeting amyloid-beta oligomers in Alzheimer's disease.

• Broad-spectrum TDP oligomer inhibitor

  A pipeline program targeting TDP oligomers, relevant to neurodegenerative diseases such as ALS.

1. 1Treventis™ Corporation - Protein Misfolding Drug Designtreventis.com
2. 2About Us - TREVENTIS™ Corporationtreventis.com
3. 3Treventis (Canada) - Wikidatawikidata.org